Press Releases

BRISBANE, Calif. , July 13, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA), a molecular diagnostics company focusing on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, announced today that the landmark

AlloMap now in-network for over 80% of covered lives with all US payors BRISBANE, Calif. , May 03, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic

PAMA to provide pricing certainty for high value diagnostic testing

CareDx further bolsters clinical evidence

Late-breaking DART data presented at ASN meeting in Chicago

Defines Cell-free DNA Levels in Stable Kidney Transplant Patients

Cell-free-DNA test identifies active rejection in kidney transplant patients

CareDx expands leadership with cfDNA for transplant care BRISBANE, Calif. , Aug. 22, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions

Alongside AlloSure Heart Validation, CareDx advances SHORE enrollment    BRISBANE, Calif. , March 11, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value

New data highlights the value of AlloSure to detect rejection in one of the most complex transplanted organs BRISBANE, Calif. , Feb. 21, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically